or Try an Advanced Search...

    Technical Analysis for STTK - Shattuck Labs, Inc.

    Grade Last Price % Change Price Change
    A 10.50 -4.28% -0.47
    STTK closed up 3.59 percent on Monday, April 29, 2024, on 1.9 times normal volume. The bulls were able to push the stock to a new 52-week high. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    Earnings due: May 7
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Up
    Historical STTK trend table...
    Date Alert Name Type % Chg
    Shooting Star Candlestick Bearish -4.28%
    Lizard Bearish Bearish Day Trade Setup -4.28%
    New 52 Week Closing High Bullish -4.28%
    Pocket Pivot Bullish Swing Setup -4.28%
    New 52 Week High Strength -4.28%
    Stochastic Reached Overbought Strength -4.28%
    Upper Bollinger Band Walk Strength -4.28%
    Above Upper BB Strength -4.28%
    Gapped Up Strength -4.28%
    Overbought Stochastic Strength -4.28%
    Older End-of-Day Signals for STTK ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown about 3 hours ago
    Down 3% about 4 hours ago
    Gap Down Partially Closed about 6 hours ago
    Gap Down Closed about 6 hours ago
    Reversed from Down about 6 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    STTK Chart by TradingView
    Basic chart:

    Profile

    Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian cancer. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was founded in 2016 and is headquartered in Austin, Texas.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Cancer Life Sciences Solid Tumors Autoimmune Disease Treatment Of Cancer Lymphoma Clinical Research Clinical Trial Ovarian Cancer Advanced Solid Tumors Clinical Pharmacology Treatment Of Ovarian Cancer

    Is STTK a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 18 Owning 36% shares,institutional owners seem interested in Shattuck Labs, Inc. (NASDAQ:STTK),
    Apr 9 Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
    Apr 1 Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference
    Mar 4 Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors
    Mar 1 Shattuck Labs GAAP EPS of -$0.41
    Feb 29 Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
    Feb 26 Shattuck Labs Announces Participation in Upcoming March Conferences
    Feb 14 Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins
    Feb 14 Two biotech/pharma stocks to watch - STTK, KALV
    Feb 13 Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases
    See more STTK news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 11.58
    52 Week Low 1.3301
    Average Volume 339,821
    200-Day Moving Average 5.26
    50-Day Moving Average 9.29
    20-Day Moving Average 9.52
    10-Day Moving Average 9.87
    Average True Range 0.68
    RSI (14) 65.40
    ADX 32.15
    +DI 39.76
    -DI 12.45
    Chandelier Exit (Long, 3 ATRs) 9.55
    Chandelier Exit (Short, 3 ATRs) 10.58
    Upper Bollinger Bands 10.69
    Lower Bollinger Band 8.35
    Percent B (%b) 1.12
    BandWidth 24.53
    MACD Line 0.33
    MACD Signal Line 0.19
    MACD Histogram 0.1379
    Fundamentals Value
    Market Cap 517.09 Million
    Num Shares 47.1 Million
    EPS -2.24
    Price-to-Earnings (P/E) Ratio -4.90
    Price-to-Sales 323.03
    Price-to-Book 3.76
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 12.19
    Resistance 3 (R3) 12.25 11.92 11.98
    Resistance 2 (R2) 11.92 11.61 11.88 11.91
    Resistance 1 (R1) 11.44 11.42 11.68 11.38 11.85
    Pivot Point 11.11 11.11 11.23 11.07 11.11
    Support 1 (S1) 10.63 10.80 10.87 10.57 10.09
    Support 2 (S2) 10.30 10.61 10.26 10.03
    Support 3 (S3) 9.82 10.30 9.96
    Support 4 (S4) 9.76